Clinical trial Recruiting at 1 site Interventional Ages 19 to 100

Personalized PEEP strategy for intrinsic PEEP during one-lung ventilation

Official title: Effects of Individualized Positive End-expiratory Pressure (PEEP) on Intrinsic PEEP and Stroke Volume During One-lung Ventilation: a Single-center, Randomized Crossover Study

Run by Samsung Medical Center · NCT07638176 · Data updated 2026-11-12

The study tests three PEEP approaches (0, 5, and a personalized level based on intrinsic PEEP) to see which best supports patients with intrinsic PEEP during lung surgery.

Quick facts

Study typeInterventional
Ages19 Years to 100 Years
SexAll
Enrollment48 (estimated)
SponsorSamsung Medical Center
Academic / other
Locations1 site (Seoul)
StatusRecruiting
StartedAugust 1, 2026
Main results expectedMay 31, 2027
Study endsMay 31, 2027
Registry record updatedSeptember 14, 2026
Trial IDNCT07638176 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (ASA I-III) undergoing lung resection with one-lung ventilation for more than 60 minutes and who develop intrinsic PEEP during ventilation.

Probably not a fit

Patients without intrinsic PEEP during one-lung ventilation or those not meeting eligibility may not benefit from this strategy.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, crossover trial compares three extrinsic PEEP settings in patients with intrinsic PEEP during one-lung ventilation for lung resection. The goal is to see how different PEEP levels affect intrinsic PEEP dynamics and hemodynamic stability. Participants are adults with COPD or related pulmonary disease undergoing lung resection, and the intervention uses a double-lumen tube with standardized ventilation protocols. The study design allows each patient to experience all three PEEP strategies to directly compare effects within individuals. Outcomes focus on iPEEP changes and cardiovascular response during the operative period.

Why it matters

Potential benefit: If successful, the trial could identify a PEEP approach that better maintains hemodynamic stability and controls intrinsic PEEP during one-lung ventilation.

How similar studies have gone: Prior work in critically ill patients suggests 70% of intrinsic PEEP as a strategy, but its applicability in intraoperative OLV is not yet proven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* American Society of Anesthesiologists Physical Status I - III
* The Eastern Cooperative Oncology Group Performance Status Grade 0 - 2
* Lung resection surgery requiring one-lung ventilation for over 60 minutes
* Indication of double-lumen endobronchial tube (female 35 Fr, male 37 Fr)
* Patient who is diagnosed with intrinsic PEEP during one-lung ventilation

Exclusion Criteria:

* Large bullae
* Emergency surgery
* Mechanical ventilation before surgery
* Hemodynamic instability before surgery
* Surgery requiring cardiopulmonary bypass
* Pregnancy, breastfeeding patient
* Patient's refusal to participate
* No intrinsic PEEP during one-lung ventilation

Where it's running

  • Samsung Medical Center
    Seoul, South Korea
    Recruiting

Study contacts

  • Principal investigator: Hyun Joo Ahn, MD, PhD — Samsung Medical Center
  • Study coordinator: Hyun Joo Ahn, MD, PhD
  • Email: hyunjooahn@skku.edu
  • Phone: +82234100784

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.